EDITAS MEDICINE, INC. Increase (Decrease) in Deferred Revenue
EDITAS MEDICINE, INC. (EDIT) reported Increase (Decrease) in Deferred Revenue of $81.71 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-08
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$3.13M, a 785.75% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$3.10M, a 2063.92% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$2.28M, a 1496.93% decline year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $90.21M, a 56997.47% increase year-over-year.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for fiscal 2017 was $81.71M, a 8638.72% increase from fiscal 2016.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for fiscal 2016 was $935.00K, a 96.31% decline from fiscal 2015.
- EDITAS MEDICINE, INC. increase (decrease) in deferred revenue for fiscal 2015 was $25.32M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$6.23M derived: sum of 2 quarters · filed 2018-03-08 | -$8.51M derived: sum of 3 quarters · filed 2018-03-08 | $81.71M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.38M derived: sum of 2 quarters · filed 2017-11-08 | $84.83M 10-Q · filed 2017-11-08 | $85.29M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $87.94M 10-Q · filed 2017-08-09 | $88.39M derived: sum of 3 quarters · filed 2018-03-08 | $88.55M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $90.21M 10-Q · filed 2017-05-15 | $90.67M derived: sum of 2 quarters · filed 2018-03-08 | $90.83M derived: sum of 3 quarters · filed 2018-03-08 | $90.99M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $614.00K derived: sum of 2 quarters · filed 2018-03-08 | $777.00K derived: sum of 3 quarters · filed 2018-03-08 | $935.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $158.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $321.00K derived: sum of 2 quarters · filed 2017-11-08 | $479.00K 10-Q · filed 2017-11-08 | $635.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $321.00K 10-Q · filed 2017-08-09 | $477.00K derived: sum of 3 quarters · filed 2018-03-08 | $609.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $158.00K 10-Q · filed 2017-05-15 | $314.00K derived: sum of 2 quarters · filed 2018-03-08 | $446.00K derived: sum of 3 quarters · filed 2018-03-08 | |
| 2015-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $288.00K derived: sum of 2 quarters · filed 2018-03-08 | $25.32M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $25.16M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $25.03M 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |